Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007806 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07007806: Completed Phase 1 study, sponsored by Atea Pharmaceuticals.
NCT07007806 is a Phase 1 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07007806, a Phase 1 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)
Primary Outcome
Cmax
Interventions
- DRUG Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting
- DRUG Treatment B-Omeprazole 20 mg dose administered fasting
- DRUG Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting
- DRUG Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole
- DRUG Treatment E-Omeprazole 40 mg administered fasting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2025-06-28 |
| Phase | Phase 1 |
What the finished NCT07007806 record still lists
NCT07007806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 5 interventions - of which Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting is the first listed.
NCT07007806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07007806 about?
NCT07007806 is a clinical study titled "Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir". Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)
What is the current status of trial NCT07007806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-05-09. Estimated completion is 2025-06-28.
What interventions are being tested in trial NCT07007806?
The interventions under investigation include: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting (DRUG), Treatment B-Omeprazole 20 mg dose administered fasting (DRUG), Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting (DRUG), Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole (DRUG), Treatment E-Omeprazole 40 mg administered fasting (DRUG).
Who is sponsoring clinical trial NCT07007806?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07007806's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI